Key Factors based on Estrogen Receptor Positive (ER+) Breast Cancer Market Analysis 2016

“Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2016”, report provides comprehensive insights about the treatment landscape across this indication. This report also provides the deep understanding of the stages of the Estrogen Receptor Positive (ER+) Breast Cancer, epidemiology, risk factors, diagnosis etc.
A key objective of the report is to establish the understanding of the treatment landscape and competitive analysis of the Estrogen Receptor Positive (ER+) Breast Cancer which mainly describes the treatment of breast cancer at different stages. Breast cancer is the condition where the cells of the breast area become tumorous, that is, they undergo unlimited cell division. Both women and men are affected but chances of men being diagnosed with breast cancer are rare. Each year about 2,300 new cases of breast cancer in men and about 230,000 new cases in women are diagnosed. It is the second most common cancer among women in USA.

Check complete report @ http://www.marketintelreports.com/report/ditl2016001/estrogen-receptor-positive-er-breast-cancer--treatment-landscape--competitive-analysis-2016

This report provides the insights of the marketed drugs for the Estrogen Receptor Positive (ER+) Breast Cancer which includes the Targeted Therapy, Hormone Therapy and Chemotherapy. In case of Estrogen Receptor Positive (ER+) Breast Cancer, Hormone therapy is the main focus of treatment after surgery and chemotherapy. Hormonal therapy is usually recommended after 5 years of surgery and can be divided into Estrogen blocking hormonal therapy and estrogen lowering hormonal therapy based on the mechanism of action of the hormonal therapy drugs. Of all the late-stage pipeline drugs, Buparlisib is expected to reach the market in the next few years.
Recent report of MarketIntelReports covers the treatment landscape which provides the treatment options by different stages and type of the breast cancer. There are four chemotherapy drugs, six hormone therapy drugs and one targeted therapy drugs in market for the treatment of Estrogen Receptor Positive (ER+) Breast Cancer.

Note: This report will be delivered to the client in 48 hours

Avail more information from Sample Brochure of report @ http://www.marketintelreports.com/pdfdownload.php?id=ditl2016001

Report Highlights:

• The new report, provides a Estrogen Receptor Positive (ER+) Breast Cancer Treatment Landscape across the globe
• The report provides profiles of the marketed drug which includes the product description, cost of treatment, development partner, patent expiry date, sales data etc.
• Comparative analysis of marketed drugs by therapy, cost of treatment, Therapeutic Class. Coverage of the Estrogen Receptor Positive (ER+) Breast Cancer Phase III and Pre-registration Drugs Analysis by product type, molecule type, route of administration, Median Progression Free Survival
• The report reviews key players involved in the therapeutics development for Estrogen Receptor Positive (ER+) Breast Cancer and also provide market barriers, market drivers and opportunities
• Provides Phase III products assessment by line of therapy and target.

Order a copy of Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2016 Report @ http://www.marketintelreports.com/purchase.php?id=ditl2016001

About us:
MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.
MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
MarketIntelReports currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.

Contact us:
Sales Manager
Mayur S.
2711 Centerville Road, Suite 400,
Wilmington,
Delaware,
19808
United States
marketintelreports.com
sales@marketintelreports.com
Telephone: 1-302-261-5343

This release was published on openPR.